ReviewEuropean journal of immunology2025
Cellular Cosmetics: How Innate Lymphoid Cells Can Recontour the Tumour Microenvironment.
Review in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Plasticity and antigen presentation by group 3 innate lymphoid cells in colorectal cancer.Frontiers in immunology · 2026Review
- Cellular Cosmetics: How Innate Lymphoid Cells Can Recontour the Tumour Microenvironment.European journal of immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The innate lymphoid cell (ILC) family includes natural killer (NK) cells, recognised for over 50 years, as well as several more recently identified populations. Over the past 15 years, ILCs have emerged as key orchestrators of tissue homeostasis and inflammation. To build upon the early promise of cancer immunotherapies, it is essential to better understand the pathways regulating the composition of, and immunosuppressive mechanisms that dominate many solid cancers and effectively curtail or block T cell responses. Given their residence within most tissues, how these cellular sentinels influence tumour development and progression remains an active area of both discovery and more translationally focused research. By defining precisely how different immunosuppressive pathways form, rationalised immunotherapy combinations can be devised to specifically target these. Current evidence indicates that for each ILC subset, both pro- and anti-tumourigenic roles are possible, likely reflecting local cues within different tissues and contexts. Here, we seek to concisely review some of the prevailing data describing ILC contributions to tumour immunity and highlight some of the challenges that still exist in fully dissecting these mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.